FDA approves Roche's Wilserdly (giredestrant) for ESR1-mutated advanced breast cancer
FROM THE WIRE · GLOBENEWSWIRE.COM
Basel, 16 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with everolimus for the treatment of adults with oestrogen receptor (ER)-positive…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn FDA approval of a new oncology drug can improve Roche's commercial outlook in the breast cancer segment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The U.S. FDA has approved Wilserdly (giredestrant) in combination with everolimus.
- 02The indication covers adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
- 03It is indicated after recurrence during or after endocrine adjuvant therapy, or progression in the metastatic setting.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets